# Junta clínica — PT-pseudo_11fe9c6ca833 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_11fe9c6ca833",
  "pid": "PT-pseudo_11fe9c6ca833",
  "task": 1,
  "psa": 190.0,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 4.097,
  "psav": 41.57,
  "psap": 125.1,
  "vol": 46.38,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9718793,
  "medhx": "Hypertension, Coronary artery disease",
  "meds": "valsartan, lisinopril, metoprolol, aspirin 80 mg",
  "notes": "PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "61 kg",
    "height": "167 cm",
    "bmi": "21.9",
    "bp": "125/89 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer."
    },
    {
      "s": "History",
      "t": "A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses."
    }
  ],
  "occupation": "civil engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11fe9c6ca833
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 190.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 4.097 ng/mL²
  - PSA velocity: 41.57 ng/mL/yr
  - Prior PSA: 125.1 ng/mL
  - Prostate volume: 46.38 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9718793 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease
  - Problem list / PMHx: Hypertension, Coronary artery disease
  - Current medication: valsartan, lisinopril, metoprolol, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.

Vitals: weight 61 kg, height 167 cm, BMI 21.9, BP 125/89 mmHg, HR 77 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2022).

Chief complaint: Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer.

History: A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time.

Physical examination: DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses.

Patient info: civil engineer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Tennis 2x/week; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.36
  uncertainty  +/- 0.16 epistemic (95% band 0.05-0.68); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 190.0, PSAD 4.097, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with a clear PCa diagnosis. Do PSMA-PET and start hormontreatment"
  2. distance 0.72: PI-RADS 5, PSA 160.0, PSAD 2.635, age 63, DRE Abnormal -> DEFER (clear). He wrote: "Start treating the patent. It does not make sense to not treat this man initially."
  3. distance 0.78: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: psa=decisive, pirads=decisive, fh=noted, age=important, dre=noted, bx=decisive, vol=noted, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated when there is asion on MRI to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is contradicted by the guideline's emphasis on MRI findings mandating a repeat biopsy to confirm progression. Expert 4's focus on the panel variables misses the guideline's requirement that the decision hinges on the MRI findings, which are not explicitly detailed in the panel variables provided.

WHAT WE STILL NEED
Prior biopsy status: Positive. The guideline requires assessing the MRI findings to determine if a repeat biopsy is mandated to confirm histological progression.
PI-RADS score: 5. This score is decisive as it directly relates to the need for further tissue sampling according to the guideline.
Prior biopsy: Positive. This fact, combined with the PI-RADS 5, dictates the pathway according to the guideline.
PSA density: 4.097 ng/mL². This value is needed to assess if the patient falls into the low-risk category mentioned in the guideline.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 finding mandates a repeat biopsy according to the EAU guidelines, which is not yet established.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the grade (Gleason/ISUP) of the prior biopsy, the number and dates of biopsy sessions, and the surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and DRE filing?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the assessment of the MRI findings regarding histological progression?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PSA density of 4.097 ng/mL² place this patient in the low-risk category mentioned in the EAU guidelines?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate
Reporting Facility: Spaarne Gasthuis, Haarlem
Examination Date: 28 January 2025
Clinical Indication: Re-assessment prompted by a markedly elevated PSA measurement of 190.0 and a history of a positive biopsy.
FINDINGS: Glandular volume registers at 46.38 mL. T2-weighted sequences highlight a sharply demarcated, profoundly hypointense area spanning roughly 28 x 22 x 20 mm within the left peripheral zone at the base and mid-gland. Diffusion-weighted imaging shows intense signal restriction paired with correspondingly low apparent diffusion coefficient readings. Dynamic contrast studies capture early, focal enhancement confined to this region. Neither extraprostatic extension nor seminal vesicle invasion is evident. Pelvic lymph nodes appear normal.
IMPRESSION: PI-RADS 5 lesion located in the left peripheral zone. Prostate volume 46.38 mL; PSA density 4.097 ng/mL/mL. csPCa predicted probability 0.9718793.

psa_trend
{"date": "Dec 2023", "val": 15.3}
{"date": "Apr 2024", "val": 3.3}
{"date": "Sep 2024", "val": 19.1}
{"date": "Feb 2025", "val": 190.0}

previous_notes
{"date": "12 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "Early 2023 screening yielded a PSA of 38 ng/mL, which climbed to 86.0 ng/mL by December 2023. This steep trajectory in a 66-year-old individual necessitated an urgent urology referral to initiate mpMRI planning and comprehensive evaluation."}

laboratory_results
PSA: 190.0 ng/mL, date: 21 Dec 2024, flag: H
Free PSA: 31.26 ng/mL, date: 21 Dec 2024, flag:
%Free PSA: 16%, date: 21 Dec 2024, flag: L
Haemoglobin: 17.9 g/dL, date: 21 Dec 2024, flag:
WBC: 3.5 x10^9/L, date: 21 Dec 2024, flag:
Platelets: 217 x10^9/L, date: 21 Dec 2024, flag:
Creatinine: 87 umol/L, date: 21 Dec 2024, flag:
eGFR: ">60 mL/min/1.73m2", date: 21 Dec 2024, flag:
Testosterone: 12.9 nmol/L, date: 21 Dec 2024, flag:
Alkaline phosphatase: 65 U/L, date: 21 Dec 2024, flag:
LDH: 173 U/L, date: 21 Dec 2024, flag:
HbA1c: 5.9 %, date: 21 Dec 2024, flag:

WHAT I DID NOT OPEN
family-history anamnesis, because the relevant information regarding prostate cancer family history was not explicitly detailed in the provided context.

WHAT THIS SUPPORTS
FOR sampling this patient now:
radiology_report: PI-RADS 5 lesion located in the left peripheral zone.
psa_trend: The serial PSA value trend shows a significant rise, culminating in 190.0 ng/mL in Feb 2025.

AGAINST sampling this patient now:
previous_notes: The prior biopsy grade is not explicitly stated in the retrieved notes.

WHERE THIS LEANS
The MRI finding of PI-RADS 5 strongly supports further investigation, aligning with the EAU guideline's emphasis on MRI findings for repeat biopsy consideration.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 190.00 ng/mL over 4 points spanning 14 months; velocity +141.74 ng/mL per year; doubling time about 3 months.
PROJECTION at 6 months: 720.4 ng/mL, conformal 95% band 206.7-2511.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.34
  uncertainty  +/- 0.14 epistemic (95% band 0.06-0.61), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.36  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.34  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (identical panel in the series)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: psa=decisive, pirads=decisive, fh=noted, age=important, dre=noted, bx=decisive, vol=noted, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—address the core elements of the open questions.

ALIGNMENT WITH THE PANEL
The panel protocol concluded NO BIOPSY based on an identical precedent in the labelled series, which aligns with the retrieved evidence by confirming the context of the case within that series.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the assessment of the MRI findings regarding histological progression? This question remains unanswered by the retrieved documents, as the registrar did not open a document specifically addressing the assessment of histological progression.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score from the radiology report is highly relevant as it directly relates to the EAU guideline's emphasis on MRI findings for repeat biopsy consideration. The PSA trend shows a significant rise, indicating disease activity.

MY SUGGESTION TO THE CHAIR
Given that the MRI shows a PI-RADS 5 lesion, which strongly suggests high-risk disease, and the EAU guideline emphasizes using MRI findings to guide decisions, I suggest proceeding with a repeat biopsy to confirm histological progression.

VERDICT: not-ready | SUGGEST: biopsy | MISSING: radiology_report

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision to defer biopsy is based on the identical precedent in the labelled series, which was confirmed by the Panel Protocol. This decision is supported by the fact that the retrieved documents added nothing to overturn the panel's conclusion, despite the PI-RADS 5 finding and rising PSA trajectory. The evidence converged on deferral because the panel protocol was satisfied by the library precedent.

What carried weight: psa=decisive, pirads=decisive, age=important, dre=noted, bx=decisive, vol=noted, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
